2021
Miscellaneous Neoplasia of the Ovary
Hui P, Banet N. Miscellaneous Neoplasia of the Ovary. Practical Anatomic Pathology 2021, 283-295. DOI: 10.1007/978-3-030-68608-6_11.Peer-Reviewed Original ResearchMetastatic carcinomaOvarian malignant epithelial tumorsPrimary ovarian lymphomaUnknown cell originSmall cell carcinomaBilateral ovarian involvementPrimary ovarian carcinomasMalignant epithelial tumorsLow-grade appearanceBreast primaryOvarian lymphomaStromal luteinizationOvarian involvementTumor thrombusCell carcinomaOvarian tumorsPrimary carcinomaAggressive tumorsCystic appearanceHypercalcemic typeMetastatic tumorsOvarian carcinomaTumor nodulesEpithelial tumorsCarcinomaNon-HPV-Associated Cervical Neoplasia
Quddus M, Ou J, Hui P. Non-HPV-Associated Cervical Neoplasia. Practical Anatomic Pathology 2021, 95-111. DOI: 10.1007/978-3-030-68608-6_4.Peer-Reviewed Original ResearchCervical adenocarcinomaHigh-risk human papilloma virusDaily practiceGestational trophoblastic tumorsHuman papilloma virusSquamous cell carcinomaUterine cervical carcinomaBiopsy/resectionTrophoblastic tumorCervical neoplasiaCell carcinomaCervical carcinomaDiagnostic challengeMetastatic tumorsPapilloma virusMalignant melanomaBenign lesionsTumorsHrHPVAdenocarcinomaCarcinomaSignificant percentagePathologistsHPVResection
2018
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors
Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAzepinesBRCA1 ProteinBRCA2 ProteinCell Line, TumorClass I Phosphatidylinositol 3-KinasesFemaleHumansMiceMutationNeoplasm MetastasisNeoplasm Recurrence, LocalOvarian NeoplasmsProteinsProto-Oncogene Proteins c-mycTriazolesTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsOvarian cancerWhole-exome sequencingC-myc amplificationRecurrent tumorsPrimary tumorBET inhibitorsChemotherapy-resistant diseaseRecurrent ovarian cancerLethal gynecologic malignancyBilateral ovarian cancerChemotherapy-resistant tumorsPrimary metastatic tumorsMutational landscapeSomatic mutationsFresh-frozen tumorsGynecologic malignanciesMetastatic tumorsPrimary cell linesC-MYC gainPIK3CA amplificationTranscoelomic metastasisTherapeutic targetPatientsMetastatic abilityTumorsMicroRNA signatures discriminate between uterine and ovarian serous carcinomas
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaDiagnosis, DifferentialFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPhenotypePredictive Value of TestsReproducibility of ResultsRetrospective StudiesTranscriptomeUterine NeoplasmsConceptsHigh-grade serous carcinomaOvarian serous carcinomaSerous carcinomaOvarian malignancyPrimary ovarian high-grade serous carcinomaOvarian high-grade serous carcinomaMiRNA signatureEndometrial serous carcinomaHigh-grade ovarian serous carcinomaUterine serous carcinomaEndometrial counterpartOvarian primaryTaqMan Low Density Array technologySynchronous primariesEndometrial cancerMetastatic tumorsCarcinomaPrimary siteSignature panelPathological determinationMicroRNA signatureSignificant discriminatory powerCancer cellsMalignancyLineage characteristics
2016
Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study
Snir OL, Buza N, Hui P. Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study. Histopathology 2016, 69: 383-392. PMID: 26952875, DOI: 10.1111/his.12959.Peer-Reviewed Original ResearchConceptsOvarian mucinous tumorsMucinous borderline tumorsMucinous tumorsBorderline tumorsMucinous carcinomaAssociated teratomaPrimary ovarian mucinous tumorsOvarian mucinous borderline tumorMucinous epithelial tumorsOvarian mature teratomaGerm cell originShort tandem repeat polymorphic lociTissue genotypingMetastatic tumorsMature teratomaEpithelial tumorsTeratomatous componentsTumor originDiagnostic utilityMetastatic onesCell originTumorsTeratomaSomatic cellsPolymorphic loci
2013
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma
Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBiomarkers, TumorBone NeoplasmsCytodiagnosisDNA, NeoplasmErbB ReceptorsFeasibility StudiesFemaleGene RearrangementHumansIn Situ Hybridization, FluorescenceLiver NeoplasmsLung NeoplasmsMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesSoft Tissue NeoplasmsYoung AdultConceptsALK gene rearrangementMetastatic lung adenocarcinomaEGFR mutationsKRAS mutationsMetastatic tumorsEpidermal growth factor receptorLung adenocarcinomaCytological specimensGene rearrangementsMolecular testsMolecular alterationsKirsten rat sarcoma viral oncogene homolog (KRAS) mutationsALK gene rearrangement analysisAnaplastic lymphoma kinase (ALK) gene rearrangementEGFR T790M mutationRat sarcoma viral oncogene homolog mutationsCases of lungT790M mutationImportant therapeutic implicationsFine needle aspiratesGene rearrangement analysisCell block materialGrowth factor receptorRecurrent lungRecurrent adenocarcinoma
2008
Primary or Secondary? Genotyping Confirmation of an Ovarian Primary Carcinoid Tumor
Dotto J, Mezzetti T, Hui P. Primary or Secondary? Genotyping Confirmation of an Ovarian Primary Carcinoid Tumor. International Journal Of Gynecological Pathology 2008, 27: 33-36. PMID: 18156971, DOI: 10.1097/pgp.0b13e318053df4.Peer-Reviewed Original ResearchConceptsPrimary carcinoid tumorCarcinoid tumorsGerm cell originCell originInsular carcinoid tumorPure histological typePrimary ovarian tumorsSignificant diagnostic challengeExtraovarian tumorMetastatic carcinoidLymphovascular invasionHistological typeOvarian tumorsMetastatic tumorsClinical managementDiagnostic challengeTeratomatous componentsGastrointestinal tractTumorsAdditional studiesDNA genotypingCarcinoidsPrognosisTractWomen